-
公开(公告)号：WO2019101665A1
公开(公告)日：2019-05-31
申请号：PCT/EP2018/081684
申请日：2018-11-19
申请人： LIPOZYT MARKER UG
IPC分类号： C12Q1/6883
CPC分类号： C12Q1/6883 , C12Q2600/112
摘要： Die Erfindung betrifft die Verwendung des relativen Wertes des Genexpressionslevels des Gens IL-6 bei der Prognose oder der Diagnose einer Diabetes mellitus Typ II Erkrankung eines Probanden. Sie betrifft ferner ein Verfahren zur Prognose und/oder die Diagnose einer Diabetes mellitus Typ II Erkrankung zur Einordnung eines Probanden in Risikogruppen, wobei das Genexpressionslevel des Gens IL-6 bestimmt wird und nachfolgend die Einordnung des Probanden unter Berücksichtigung dieses Genexpressionslevels in Risikogruppen erfolgt.
-
公开(公告)号：WO2018213296A1
公开(公告)日：2018-11-22
申请号：PCT/US2018/032748
申请日：2018-05-15
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158
摘要： A genetic panel to molecularly classify diffuse gliomas is described. The genetic panel includes assessments of chromosome copy number alterations and genetic sequences associated with cell cycle progression. The genetic panel distinguishes between eight distinct forms of glioma.
-
公开(公告)号：WO2018209058A1
公开(公告)日：2018-11-15
申请号：PCT/US2018/032029
申请日：2018-05-10
IPC分类号： A61K39/395 , A61P35/02 , C07K16/30 , G01N15/14 , G01N33/574 , C12Q1/68
CPC分类号： A61P35/02 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , G01N33/57426 , G01N2800/52
摘要： Methods for diagnosing, treating and monitoring chronic lymphocytic leukemia based on intraclonal or interclonal CLL diversity and quantitation.
-
4.发明申请
公开(公告)号：WO2018174863A1
公开(公告)日：2018-09-27
申请号：PCT/US2017/023478
申请日：2017-03-21
申请人： MPROBE INC.
发明人： LING, Bruce, Xuefeng , CHEN, Limin , HAO, Shiying
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/57419
摘要： Colon cancer markers, colon cancer marker panels, and methods for obtaining a colon cancer marker level representation for a sample are provided, based upon RNAseq expression profiling. These composition and methods find use in a number of applications, including, for example, diagnosing colon cancer, prognosing colon cancer, monitoring a subject with colon cancer, and determining a treatment for colon cancer. In addition, systems, devices, and kits thereof that find use in practicing the subject methods are provided.
-
5.发明申请
公开(公告)号：WO2018174862A1
公开(公告)日：2018-09-27
申请号：PCT/US2017/023476
申请日：2017-03-21
申请人： MPROBE INC.
发明人： LING, Bruce, Xuefeng , CHEN, Limin , HAO, Shiying
CPC分类号： C12Q1/6886 , C07H21/00 , C12Q1/68 , C12Q2600/112 , C12Q2600/158
摘要： Bladder cancer markers, bladder cancer marker panels, and methods for obtaining a bladder cancer marker level representation for a sample are provided, based upon RNAseq expression profiling. These composition and methods find use in a number of applications, including, for example, diagnosing bladder cancer, prognosing bladder cancer, monitoring a subject with bladder cancer, and determining a treatment for bladder cancer. In addition, systems, devices, and kits thereof that find use in practicing the subject methods are provided.
-
6.发明申请
公开(公告)号：WO2018174861A1
公开(公告)日：2018-09-27
申请号：PCT/US2017/023475
申请日：2017-03-21
申请人： MPROBE INC.
发明人： LING, Bruce, Xuefeng , CHEN, Limin , HAO, Shiying
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158
摘要： Breast cancer markers, breast cancer marker panels, and methods for obtaining a breast cancer marker level representation for a sample are provided, based upon RNAseq expression profiling. These composition and methods find use in a number of applications, including, for example, diagnosing breast cancer, prognosing breast cancer, monitoring a subject with breast cancer, and determining a treatment for breast cancer. In addition, systems, devices, and kits thereof that find use in practicing the subject methods are provided.
-
公开(公告)号：WO2018144216A1
公开(公告)日：2018-08-09
申请号：PCT/US2018/013949
申请日：2018-01-17
申请人： COUNSYL, INC.
发明人： LAI, Henry, H. , CHU, Clement, S.
CPC分类号： C12N15/1093 , C12Q1/6806 , C12Q1/6855 , C12Q1/686 , C12Q2600/112 , C12Q2600/124 , C12Q2521/319 , C12Q2525/125 , C12Q2563/179 , C12Q2565/519
摘要： High-fidelity, high-throughput nucleic acid sequencing enables healthcare practitioners and patients to gain insight into genetic variants and potential health risks. However, previous methods of nucleic acid sequencing often introduces sequencing errors (for example, mutations that arise during the preparation of a nucleic acid library, during amplification, or sequencing). Provided herein are methods and compositions for sequencing nucleic acids. Further provided are methods of identifying an error in a nucleic acid sequence.
-
8.发明申请LEVERAGING THE PRESENCE OR ABSENCE OF MIRNA ISOFORMS FOR RECOMMENDING THERAPY IN CANCER PATIENTS 审中-公开利用MIRNA异形的存在或缺乏推荐用于癌症患者的治疗
公开(公告)号：WO2018076015A1
公开(公告)日：2018-04-26
申请号：PCT/US2017/057909
申请日：2017-10-23
IPC分类号： C12Q1/68 , G01N1/30 , G01N33/48 , G01N33/483 , G01N33/487 , G01N33/50 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , C12Q2600/178 , G01N1/30 , G01N33/50 , G16H50/20 , G16H50/30
摘要： A method of identifying a subject in need of therapeutic intervention to treat a disease or condi-tion or disease recurrence or disease progression comprising, isolating isomiRs or miRNAs from a sample obtained from the subject; and characterizing the isomiRs or miRNAs and their presence or absence in the sample to identify a signature, wherein when the signature is indicative of a di-agnosis of the disease then treatment of the subject is recommended.
摘要翻译： 鉴定需要治疗性干预以治疗疾病或病症或疾病复发或疾病进展的受试者的方法，其包括从获自所述受试者的样品中分离同种异型糖或miRNA; 和表征样品中的isomR或miRNA及其存在或不存在以鉴定标记，其中当标记指示疾病的di-agnosis时，推荐对受试者进行治疗。
-
9.发明申请METHODS AND KITS COMPRISING GENE SIGNATURES FOR STRATIFYING BREAST CANCER PATIENTS 审中-公开方法和试剂盒包含基因签名分类乳腺癌患者
公开(公告)号：WO2017220492A1
公开(公告)日：2017-12-28
申请号：PCT/EP2017/064937
申请日：2017-06-19
申请人： ISTITUTO EUROPEO DI ONCOLOGIA (IEO) , FONDAZIONE FIRC PER I'ONCOLOGIA MOLECOLARE (IFOM) , UNIVERSITA DEGLI STUDI DI MILANO (UNIVERSITY OF MILAN)
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , C12Q2600/166 , G16B5/00 , G16B40/00
摘要： The present invention relates to refined prognostic clinical tools, methods, and kits for the evaluation of risk and treatment of distant recurrence in ER+/HER2- breast cancer patients.
摘要翻译： 本发明涉及用于评估ER + / HER2-乳腺癌患者中远处复发的风险和治疗的改进的预后临床工具，方法和试剂盒。
-
公开(公告)号：WO2017132673A1
公开(公告)日：2017-08-03
申请号：PCT/US2017/015643
申请日：2017-01-30
申请人： APTE, Rajendra S. , YOSHINO, Jun
发明人： APTE, Rajendra S. , YOSHINO, Jun
IPC分类号： C07K14/475 , G01N33/487 , C12Q1/68 , A61P27/06
CPC分类号： C07K14/475 , C12Q1/6883 , C12Q2600/112 , C12Q2600/158
摘要： The present disclosure provided methods for determining the severity of glaucoma using the expression levels of GDF15. Determining the severity of glaucoma aids in treatment decisions.
摘要翻译： 本公开提供了使用GDF15的表达水平确定青光眼严重程度的方法。 确定青光眼的严重程度有助于治疗决策。
-
-
-
-
-
-
-
-
-
搜索结果
2726 条记录 (耗时 0.054 秒)
